TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Recommendation of "Buy" by Brokerages

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) has been assigned an average recommendation of "Buy" from the eight analysts that are presently covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $10.75.

TLSI has been the subject of several recent research reports. Lake Street Capital initiated coverage on shares of TriSalus Life Sciences in a research note on Thursday, February 13th. They issued a "buy" rating and a $10.00 price target for the company. Canaccord Genuity Group reissued a "buy" rating and issued a $11.00 price target on shares of TriSalus Life Sciences in a research note on Friday, March 28th.

TriSalus Life Sciences Price Performance

TLSI opened at $5.39 on Friday. The company has a fifty day moving average price of $5.39 and a 200-day moving average price of $5.13. The firm has a market capitalization of $203.95 million, a P/E ratio of -2.16 and a beta of 0.47. TriSalus Life Sciences has a one year low of $3.50 and a one year high of $6.62.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.13). The firm had revenue of $9.17 million for the quarter, compared to the consensus estimate of $9.04 million. During the same period in the prior year, the company earned ($0.60) earnings per share. On average, analysts expect that TriSalus Life Sciences will post -1.55 earnings per share for the current year.

Insider Buying and Selling at TriSalus Life Sciences

In related news, insider Richard Marshak sold 6,597 shares of the company's stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $5.18, for a total transaction of $34,172.46. Following the transaction, the insider now directly owns 69,101 shares in the company, valued at approximately $357,943.18. This represents a 8.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have sold 16,125 shares of company stock worth $83,528. Insiders own 27.50% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of TLSI. Charles Schwab Investment Management Inc. acquired a new stake in shares of TriSalus Life Sciences in the first quarter worth $55,000. Renaissance Technologies LLC purchased a new stake in TriSalus Life Sciences during the fourth quarter worth $67,000. Connective Capital Management LLC purchased a new stake in TriSalus Life Sciences during the fourth quarter worth $140,000. Northern Trust Corp boosted its holdings in TriSalus Life Sciences by 22.7% during the fourth quarter. Northern Trust Corp now owns 32,112 shares of the company's stock worth $161,000 after buying an additional 5,936 shares in the last quarter. Finally, Goldman Sachs Group Inc. purchased a new stake in TriSalus Life Sciences during the first quarter worth $187,000. Institutional investors own 2.58% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.